Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neuphoria Therapeutics (NEUP) Return on Sales (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Return on Sales for 1 consecutive years, with 0.8% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Sales changed N/A to 0.8% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.8%, a N/A change, with the full-year FY2025 number at 0.42%, changed N/A from a year prior.
  • Return on Sales was 0.8% for Q4 2025 at Neuphoria Therapeutics, up from 1.05% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 1142.47% in Q2 2025 to a low of 1.05% in Q3 2025.